MOMORDICA CHARANTIA NANO DRY POWDER ORAL FORMULATION IN CONTROLLING HISTAMINE-INDUCED BRONCHOSPASM
Objective: Momordica charantia (MC) (bitter gourd) is known traditionally to possess medicinal values. This edible vegetable is known for its anti-inflammatory properties and has been studied for its bronchospasm preventive action. With the recent development in nanoformulations, this study was done to identify the effectiveness of MC nanoformulation in comparison to crude MC formulation in protecting animal from histamine-induced bronchospasm.
Methods: The optimized MC nanoformulation was prepared with polyethylene glycol and soy phosphatidylcholine. The MC crude powder was prepared by drying in hot air oven and grinding in a blender. Eight guinea pigs of both sexes were given once daily MC nanoformulation per oral by mixing with water for 7 days. Evaluation of the formulation was done on the 2nd, 4th, and 6th h on day 1 and day 7 after administration of MC for protection in developing pre-convulsive dyspnea due to histamine-induced bronchospasm.
Results: An analysis of variance test revealed statistically significant results in the protection of animals from developing bronchospasm after treatment with the MC nanoformulation in comparison to the control values. About 75% of animals were protected from developing bronchospasm on day 7 attributing to the cumulative effect of nanoformulation.
Conclusion: The study proved that the MC nanoformulation could effectively prevent histamine-induced bronchospasm in guinea pigs.
2. Sathishsekar D, Subramanian S. Antioxidant properties of Momordica charantia (bitter gourd) seeds on streptozotocin induced diabetic rats. Asia Pac J Clin Nutr 2005;14:153-8.
3. Senanayake GV, Maruyama M, Shibuya K, Sakono M, Fukuda N, Morishita T, et al. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J Ethnopharmacol 2004;91:257-62.
4. Cunnick JE, Sakamoto K, Chapes SK, Fortner GW, Takemoto DJ. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia). Cell Immunol 1990;126:278-89.
5. Srivastava AK, Mishra A, Gautam S, Pal S, Mishra A, Kumar AR, et al. Effect of Momordica charantia fruits on streptozotocin-induced diabetes mellitus and its associated complications. Int J Pharm Pharm Sci 2015;7:356-63.
6. Navya G, Shirisha Y, Girija P, Venkateshwarlu K, Sirisha K. Effect of Momordica charantia and Syzygium cumini extract on serum electrolytes in alloxan induced diabetic rats. Int J Pharm Pharm Sci 2018;11:24-7.
7. Frossard N, Freund V, Advenier C. Nerve growth factor and its receptors in asthma and inflammation. Eur J Pharmacol 2004;500:453-65.
8. Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: Recent progress and remaining concerns. Expert Opin Drug Deliv 2014;11:139 54.
9. Singh U, Sagar VR. Effect of drying methods on nutritional composition of dehydrated bitter gourd (Momordica charantia). Indian agricultural research institute, New Delhi-12. Agric Sustain Dev 2013;1:83-86.
10. Tiruwa R. A review on nanoparticles-preparation and evaluation parameters. Indian J Pharm Biol Res 2016;4:27-8.
11. Pinzaru I, Coricovac D, Dehelean C, Moac? EA, Mioc M, Baderca F, et al. Stable PEG-coated silver nanoparticles a comprehensive toxicological profile. Food Chem Toxicol 2018;111:546-56.
12. Singh S, Agrawal SS. Anti-asthmatic and anti-inflammatory activity of Ocimum sanctum. Int J pharm 1991;29:306-10.
13. Sridevi G, Gopkumar P, Ashok S, Shastry C. Pharmacological basis for antianaphylactic, antihistaminic and mast cell stabilization activity of Ocimum sanctum. Internet J. Pharmacol 2009;7:22-5.
14. Bhuvaneswari K, Swarna RM, Amudhan A. Anti asthmatic effect of Momordica charantia and its comparison with montelukast an in vitro and in vivo model. Int J Basic Clin Pharmacol 2017;6:1810-5.
15. Ichinose M, Barnes PJ. Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo. Eur J Pharmacol 1989;174:49-55.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.